PATENT CLAIM ANALYSIS

Application Number: 15996697
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "218000"]

Abstract:
The present invention generally relates to inhibitor compounds and their use to selectively kill a class of cancer cells. Methods and means related to the treatment of cancers which overexpress the MYC family of oncogenes using Rho-associated protein kinase inhibitors, such as dimethylfasudil, which have shown to elicit cellular apoptosis, are provided herein.

Claim (Index 2):
The method of  claim 1 , wherein said ROCK inhibitor is dimethyfasudil.

Metadata:
- Claim Count in Document: 30.0
- Percentile: 94.0
- Lexical Diversity: 1.23404
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13639258', '14237838', '15712849', '13439830', '11869634']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7603510499731816
- 35 USC 102 Novelty (BERT): 0.5090305158920293
- Combined Prediction Score: 0.7352189965650664
- Mean Citation Score: 258.979466
- Max Citation Score: 281.2789
- Similarity Product: 212.75483020915988

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test